DELHI, India, Sept. 23, 2020 (GLOBE NEWSWIRE) -- :
"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:
- Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
- Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
- Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
- Global Bispecific Antibody Pipeline: 333 Drug
- Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
- Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%
Download Report:
https://www.kuickresearch.com/report-global-bispecific-antibody-market-opportunity,-drug-sales--and-clinical-trials-insight-2026.php
The healthcare landscape all over world is shifting rapidly to a paradigm that is now more declined towards use of antibody for the treatment of cancer. The proliferation observed in the global bispecific antibody market in the past few years with respect to size and overall growth has broken all the records as the advent of technology that targets two different epitopes simultaneously has increased the overall success rate generated over the other therapies. The market of bispecific antibodies and all the drivers associated with it have been driving the unstructured treatment regimen in cancer therapies towards more structured and reliable one.
In terms of progression and growth observed in the market different medical centers around the world have been playing important role in the development of several clinical trials for novel bispecific antibodies with respect to more advanced cancers. The arrival of the market is believed to be developed to conquer the difficulties that have been observed with other old and traditional therapies regarding target specificity. Not only, the specificity delivered by the drugs is helping the market to attain more reliable and potential patients but there are various different parameters are driving the market of bispecific antibodies. Some of the parameters that are driving the market potential include: increasing prevalence of cancer cases, increased failure rate of other cancer therapies and rising geriatric population.
All the above-mentioned factors have helped the researchers to develop strategies and arrive with a therapeutic class that can target different types of cancer effectively. With time, the academic as well as the community world associated with the pharmaceutical industry have come far to customize the approach with respect to the need of the patient population. Various leading centers in the world have already established themselves as a super-power for bispecific antibodies and many have been on the corner to integrate with the market and deliver more potent bispecific antibodies for the benefit of the cancer patients all across the globe. The expansion of the market is also aided by the general collaborations that has been taking place since the arrival of the market strategically.
As per the report findings, it can be observed that the partnerships that have been taking place in order to expand the applications of the bispecific antibodies to the fullest is one important factor that is analyzed to have a strong connection with growing appreciation and acceptance of the therapy around the world as a standard one. The better understanding of the applications and the available potential drugs have helped the market to get incorporated into a top-approach in the clinical care pathway. The adoption of the tools that can be used to make bispecific antibodies is also estimated to be driving the market to the fullest. The competitive position and the better vision to understand the need of the patients is estimated to cause a shift in the cancer care landscape that is growing unexpectedly. The future of the drugs that are under review process are estimated to reorganize the sales forces of the market to a level that will not be defendable.
Contact:
Neeraj chawla
neeraj@kuickresearch.com
+91-9810410366
Table of Contents
1. Introduction to Bispecific Monoclonal Antibody
1.1 Overview of Monoclonal Antibody
1.2 Overview of Bispecific Monoclonal Antibody
1.3 Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies
2. The Engineering & Development of Bispecific Antibodies
2.1 Bispecific Antibodies Similar to IgG
2.1.1 Quadroma (Hybrid Hydromas) Approach
2.1.2 “Knobs Into Holes” Approach
2.1.3 CrossMab Approach
2.1.4 Dual-Variable-Domain Immunoglobulin Approach
2.2 Small Bispecific Antibodies
2.2.1 Bispecific Diabodies
2.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)
3. Mechanism Of Action Of Bispecific Antibody
3.1 Trifunctional Antibody: Catumaxomab (Removab®)
3.2 Blinatumomab
4. Applications of Bispecific Antibodies in Diagnostic & Treatment
4.1 BsMAb for Diagnosis of Bacterial & Viral Infectious Diseases
4.2 BsMAb for Cancer Diagnostic
4.3 BsAbs Blocking Signaling Pathways
4.4 BsAbs Targeting Tumor Angiogenesis
4.5 Specific Delivery of Effector Compounds to Targets
4.6 Bispecific Antibodies & Gene Therapy
5. Global Bispecific Antibody Market Outlook
5.1 Current Market Scenario
5.2 Availability of Bispecific Antibodies
5.2.1 Catumaxomab (Removab)
5.2.2 Blinatumomab
5.2.3 Emicizumab
5.2.4 Duligotumab
5.2.5 SAR 156597
6. Approved Bispecific Antibody Dosage & Price Analysis
6.1 Blincyto
6.2 Hemlibra
7. Approved Bispecific Antibody Sales Analysis
7.1 Blincyto
7.2 Hemlibra
8. Global Bispecific Antibodies Clinical Pipeline Overview
8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 Orphan Designated Bispecific Antibodies
9. Global Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
10. Marketed Bispecific Antibodies Clinical Insight
10.1 Blinatumomab - Amgen
10.2 Emicizumab - Chugai Pharmaceutical
11. Global Bispecific Antibody Market Dynamics
11.1 Favorable Market Parameters
11.2 Commercialization Challenges
12. Global Bispecific Antibody Market Future Prospects
13. Competitive Landscape
13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune SA
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi